contact@scholarena.com
+1-6602142040
Indexing | Open Access Testimonials Track Your Article

Journal of Psychiatry Studies

Submit Manuscript
  • Home
  • Aim & Scope
  • Editorial Board
  • Instructions
    • For Authors
    • For Editors
    • For Reviewers
  • Volumes & Issues
    • Articles in Press
    • Current Issue
    • Archive

x1. Lieberman JA, First MB (2018) Psychotic Disorders. N Engl J Med 379: 270-80.
x2. McKee J, Brahm N (2016) Medical mimics: Differential diagnostic considerations for psychiatric symptoms. Ment Health Clin 6: 289-96.
x3. Addington J, Cornblatt BA, Cadenhead KS, Cannon TD, McGlashan TH, et al. (2011) At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry 168: 800-5.
x4. Buchy L, Cadenhead KS, Cannon TD, Cornblatt BA, McGlashan TH, et al. (2015) Substance use in individuals at clinical high risk of psychosis. Psychol Med 45: 2275-84.
x5. Smith B, Dubovsky SL (2017) Pharmacotherapy of mood disorders and psychosis in pre- and post-natal women. Expert Opin Pharmacother 16: 1703-19.
x6. Chen B, Choi H, Hirsch LJ, Katz A, Legge A, et al. (2017) Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav 76: 24-31.
x7.White HS (2003) Mechanism of action of newer anticonvulsants. J Clin Psychiatry 64: 5-8.
x8. Manhapra A, Chakraborty A, Arias AJ (2018) Topiramate Pharmacotherapy for Alcohol Use Disorder and Other Addictions: A Narrative Review. J Addict Med.
x9. Singh T (2006) Topiramate and psychosis. Psychiatry 12: 10-7.
x10. Gupta PP, Thacker AK, Haider J, Dhawan S, Pandey N, et al. (2014) Assessment of topiramate’s efficacy and safety in epilepsy. J Neurosci Rural Pract 2: 144-8.
x11. Mowla A, Pani A (2010) Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial. J Clin Psychopharmacol 30: 40-3.
x12. Khan A, Faught E, Gilliam F, Kuzniecky R (1999) Acute psychotic symptoms induced by topiramate. Seizure 8: 235-7.
x13. Miller AD, Prost VM, Bookstaver PB, Gaines KJ (2010) Topiramate-induced myoclonus and psychosis during migraine prophylaxis. AmJHealth Syst Pharm 67:1178-80.
x14. Watkin A, Alam F, Qaiser J (2010) Topiramate-induced psychosis: the picture at 12 months. BMJ Case Rep : 0720103141.
x15. Kanner AM, Wuu J, Faught E, Tatum WO, Fix A, et al. (2003) A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav 4: 548-52.
x16. Grandone A, Di Sessa A, Umano GR, Toraldo R, Miraglia Del Giudice E (2018) New treatment modalities for obesity.Best Pract Res Clin Endocrinol Metab 32: 535-49.
x17. Iwaki H, Jin K, Fujikawa M, Nakasato N, Kaneko S (2018) Topiramate-induced weight loss depends on level of intellectual disability in patients with epilepsy.Epilepsy Behav 83: 87-91.
x18. Patel DK, Stanford FC (2018) Safety and tolerability of new-generation anti-obesity medications: a narrative review. Postgrad Med 130: 173-82.
x19. Khera R, Pandey A, Chandar AK, Murad MH, Prokop LJ, et al. (2018) Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis.Gastroenterol 154: 1309-19.
x20. Lai YH, Ding YJ, Moses D, Chen YH (2017) Teratogenic Effects of Topiramate in a Zebrafish Model. Int J Mol Sci E1721.
x21. Kaufman KR, Newman NB, Dawood A (2014) Capgras delusion with violent behavior in Alzheimer dementia: case analysis with literature review.Ann Clin Psychiatry 26: 187-91.
x22. Theitler J, Brik A, Shaniv D, Berkovitch M, Gandelman-Marton R (2017) Antiepileptic Drug Treatment in Community-Dwelling Older Patients with Epilepsy: A Retrospective Observational Study of Old- Versus New-Generation Antiepileptic Drugs. Drugs Aging 34: 479-87.
x23. Bonnett L, Smith CT, Smith D, Williamson P, Chadwick D, et al. (2012) Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial. Lancet Neurol 11: 331-40.
x
9. Singh T (2006) Topiramate and psychosis. Psychiatry 12: 10-7.
10. Gupta PP, Thacker AK, Haider J, Dhawan S, Pandey N, et al. (2014) Assessment of topiramate’s efficacy and safety in epilepsy. J Neurosci Rural Pract 2: 144-8.
11. Mowla A, Pani A (2010) Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial. J Clin Psychopharmacol 30: 40-3.
x
12. Khan A, Faught E, Gilliam F, Kuzniecky R (1999) Acute psychotic symptoms induced by topiramate. Seizure 8: 235-7.
13. Miller AD, Prost VM, Bookstaver PB, Gaines KJ (2010) Topiramate-induced myoclonus and psychosis during migraine prophylaxis. AmJHealth Syst Pharm 67:1178-80.
14. Watkin A, Alam F, Qaiser J (2010) Topiramate-induced psychosis: the picture at 12 months. BMJ Case Rep : 0720103141.
15. Kanner AM, Wuu J, Faught E, Tatum WO, Fix A, et al. (2003) A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav 4: 548-52.
x
16. Grandone A, Di Sessa A, Umano GR, Toraldo R, Miraglia Del Giudice E (2018) New treatment modalities for obesity.Best Pract Res Clin Endocrinol Metab 32: 535-49.
17. Iwaki H, Jin K, Fujikawa M, Nakasato N, Kaneko S (2018) Topiramate-induced weight loss depends on level of intellectual disability in patients with epilepsy.Epilepsy Behav 83: 87-91.
18. Patel DK, Stanford FC (2018) Safety and tolerability of new-generation anti-obesity medications: a narrative review. Postgrad Med 130: 173-82.
x
21. Kaufman KR, Newman NB, Dawood A (2014) Capgras delusion with violent behavior in Alzheimer dementia: case analysis with literature review.Ann Clin Psychiatry 26: 187-91.
22. Theitler J, Brik A, Shaniv D, Berkovitch M, Gandelman-Marton R (2017) Antiepileptic Drug Treatment in Community-Dwelling Older Patients with Epilepsy: A Retrospective Observational Study of Old- Versus New-Generation Antiepileptic Drugs. Drugs Aging 34: 479-87.
x
54. Penha AM, Burkhardt E, Schaeffel F, Feldkaemper MP (2012) Effects of intravitreal insulin and insulin signaling cascade inhibitors on emmetropization in the chick. Mol Vis18: 2608-22.
55. Lin SF, Lin PK, Chang FL, Tsai RK (2009) Transient hyperopia after intensive treatment of hyperglycemia in newly diagnosed diabetes. Ophthalmologica 223: 68-71.
56. Feldkaemper MP, Neacsu I, Schaeffel F (2009) Insulin acts as a powerful stimulator of axial myopia in chicks. Invest Ophthalmol Vis Sci 50: 13-23.
57. Zhu ZC, Zhang JS, Ji XY, Wang YF, Chen Y, et al. (2007) Insulin-like growth factor-1 induced activation and expression of signal transducers and activators of transcription-3 in scleral fibroblast of guinea pigs [Article in Chinese]. Zhonghua Yan Ke Za Zhi 43: 1125-9.
x
81. Grenet T, Streho M, Nicolon L, Puech M, Chaine G (2011) A case report of transient myopia following blunt trauma [Article in French]. J Fr Ophtalmol 34: 127.e1-4.
82. Küchle M, Naumann GO (2003) Transient myopia after trauma. Ophthalmology 110: 1285-6.
83. Ikeda N, Ikeda T, Nagata M, Mimura O (2002) Pathogenesis of transient high myopia after blunt eye trauma. Ophthalmology 109: 501-7.
84. Doğanay S, Er H, Hepşen IF, Evereklioğlu C (2001) Bilateral myopia following blunt trauma to one eye. Eur J Ophthalmol 11: 83-5.
85. Guerriero S, Ciracì L, Cardia G, Vetrugno M (2010) Transient myopic shift as the presenting symptom of systemic lupus erythematosus: a UBM study. Ocul Immunol Inflamm 18: 383-4.
x
86. Hung KC, Hsueh PY, Wang NK, Su WW, Tan HY (2011) Transient myopic shifting in systemic lupus erythematosus. Lupus 20: 334-5.
87. Bohgaki T, Mukai M, Notoya A, Kondo M, Kohno M, et al. (2001) Transient myopia with severe chemosis as an initial manifestation of systemic lupus erythematosus. Mod Rheumatol 11: 165-7.
88. Shu U, Takeuchi F, Tanimoto K, Moroi Y, Uchida K, et al. (1992) Transient myopia with severe chemosis associated with exacerbation of disease activity in systemic lupus erythematosus. J Rheumatol 19: 297-301.
x
x13. Hall W, Degenhardt L (2007) Prevalence and correlates of cannabis use in developed and developing countries. Curr Opin Psychiatry 20: 393-7.
x14. Weir E (2000) Raves: a review of the culture, the drugs and the prevention of harm. CMAJ 162: 1843-8.
x15. Van Havere T, Vanderplasschen W, Broekaert E, De Bourdeaudhui I (2009) The Influence of Age and Gender on Party Drug Use Among Young Adults Attending Dance Events, Clubs, and Rock Festivals in Belgium. Substance Use & Misuse 44: 1899-915.
x16. Van Havere T, Vanderplasschen W, Lammertyn J, Broekaert E, Bellis M (2011) Drug use and nightlife: more than just dance music. Subst Abuse Treat Prev Policy 6: 18.
x17. Donath C, Gräßel E, Baier D, Pfeiffer C, Karagülle D, et al. (2011) Alcohol consumption and binge-drinking in adolescents: comparison of different migration backgrounds and rural vs. urban residence-a representative study. Donath et al. BioMed Central (BMC) Public Health 11: 84
x18. Fergusson DM, Lynskey MT, Horwood LJ (1996) Alcohol misuse and juvenile offending in adolescence. Addiction 91: 483-94.
x
x23. Duke A A, Smith K M Z, Oberleitner L M S, Westphal A, McKee S A (2018) Alcohol, drugs, and violence: A meta-meta-analysis. Psychology of Violence 8: 238-49.
x24. Marihuana: A Signal of Misunderstanding (1972) National Commission on Marihuana and Drug Abuse. Chapter III. Social Impact of Marihuana Use. Report. Commissioned by President Richard M. Nixon, March, 1972. Iova University.
x25. Killias M, Kuhn A, Aebi MF (2011) Ground plan of criminology. A European perspective (Grundriss der Kriminologie. Eine Europeische Perspektive) 2nd edn. Bern: Stämpfli Verlag AG Bern.
x
x27. Pliner P, Cappell H, Miles CG (1972) Observer judgments of intoxicated behavior during social interaction: a comparison of alcohol and marijuana, in Drug Addiction, edited by Singh JM, Miller LH, Lal H Mt. Kisco, NY: Futura Publishing, 1972, pp 59-67. Quoted by Moss HB, Tarter RE (1993) Substance Abuse, I Aggression, and Violence. What Are the Connections? The American J Addict 2:149-60.
x28. Reiss A J, Roth J A (1993) Alcohol, other psychoactive drugs and violence. In A J Reiss, J A Roth (Eds.), Understanding and preventing violence.Washington, DC: National Academy Press: 182–220.
x29. Boles SM, Miotto K (2003) Substance abuse and violence: A review of the literature. Aggression and violent behavior 8: 155-74.
x
x30. Otero-Lopez JM, Luengo-Martin A, Miron-Redondo L, Carrillo-De-La-Peña M T, Romero-Trinanes E (1994) An Empirical Study of the Relations Between Drug Abuse and Delinquency Among Adolescents. Br J Criminol 34: 459-78.
x31. Calafat A, Mantećon A, Juan M, Adrover-Roig D, Blay N, et al. (2011) Violent Behaviour, Drunkness, Drug use, and Social Capital in Nightlife Context. Psychosocial Intervention 20: 45-51.
x32. Hoaken PN, Stewart SH (2003) Drugs of abuse and the elicitation of human aggressive behavior. Addictive behavior 28: 1533-54.
x33. Roth J A (1994) Psychoactive Substances and Violence. Research in Brief, US Dept. of Justice.
x34. Manzoni P, Lucia S, Schwarzenegger C (2011) Feasibility study on the dark field survey in the area of “youth and violence”. Final Report. On behalf of the Federal Social Insurance Office (BSV). Criminological Institute University of Zurich (Machbarkeitsstudie zur Dunkelfeldbefragung im Bereich “Jugend und Gewalt”. Schlussbericht. Im Auftrag des Bundesamts für Sozialversicherungen (BSV). Kriminologisches Institut Universität Zürich) 149.
x35. Moore T M, Gregory L S (2005) Review of the literature on marijuana and interpersonal violence. Aggression and Violent Behavior 10: 171-92.
x
x14. Weir E (2000) Raves: a review of the culture, the drugs and the prevention of harm. CMAJ 162: 1843-8.
x15. Van Havere T, Vanderplasschen W, Broekaert E, De Bourdeaudhui I (2009) The Influence of Age and Gender on Party Drug Use Among Young Adults Attending Dance Events, Clubs, and Rock Festivals in Belgium. Substance Use & Misuse 44: 1899-915.
x16. Van Havere T, Vanderplasschen W, Lammertyn J, Broekaert E, Bellis M (2011) Drug use and nightlife: more than just dance music. Subst Abuse Treat Prev Policy 6: 18.
x
x46. RCT – randomized controlled trial.
x47. Kivivuori J, Salmi V, Walser S (2013) Supervision mode effects in computerized delinquency surveys at school: Finnish replication of a Swiss experiment. Journal of Experimental Criminology 9: 91-107.
x48. Walser S, Killias M (2012) Who should supervise students during self-report interviews? A controlled experiment on response behavior in online questionnaires. J Exp Criminol 8: 17-28.
x
x14. Weir E (2000) Raves: a review of the culture, the drugs and the prevention of harm. CMAJ 162: 1843-8.
x15. Van Havere T, Vanderplasschen W, Broekaert E, De Bourdeaudhui I (2009) The Influence of Age and Gender on Party Drug Use Among Young Adults Attending Dance Events, Clubs, and Rock Festivals in Belgium. Substance Use & Misuse 44: 1899-915.
x16. Van Havere T, Vanderplasschen W, Lammertyn J, Broekaert E, Bellis M (2011) Drug use and nightlife: more than just dance music. Subst Abuse Treat Prev Policy 6: 18.
x17. Donath C, Gräßel E, Baier D, Pfeiffer C, Karagülle D, et al. (2011) Alcohol consumption and binge-drinking in adolescents: comparison of different migration backgrounds and rural vs. urban residence-a representative study. Donath et al. BioMed Central (BMC) Public Health 11: 84
x18. Fergusson DM, Lynskey MT, Horwood LJ (1996) Alcohol misuse and juvenile offending in adolescence. Addiction 91: 483-94.
x
x6. Police Crime Statistics (PKS) (2013) Annual Report 2012. Section Crime and Criminal Law. Federal Statistical Office (FSO) (Polizeiliche Kriminalstatistik (PKS) (2013). Jahresbericht 2012. Sektion Kriminalität und Strafrecht. Herausgeber - Bundesamt für Statistik (BFS)). Neuchâtel.
x7. Police Crime Statistics (PKS) (2014) Annual Report 2013. Crime and Criminal Justice Section. Federal Statistical Office (FSO) (Polizeiliche Kriminalstatistik (PKS) (2014). Jahresbericht 2013. Sektion Kriminalität und Strafrecht. Herausgeber - Bundesamt für Statistik (BFS)). Neuchâtel.
x8. Police Crime Statistics (PKS) (2015) Annual Report 2014 Crime and Criminal Law Section. Federal Statistical Office (FSO) (Polizeiliche Kriminalstatistik (PKS) (2015) Jahresbericht 2014. Sektion Kriminalität und Strafrecht. Herausgeber - Bundesamt für Statistik (BFS)). Neuchâtel.
x9. Killias M (1997) Immigrants, crime, and criminal justice in Switzerland. In M. Tonry (Ed.), Ethnicity, crime, and immigration: Comparative and cross-national perspectives. Chicago: University of Chicago Press: 375-406.
x10. Vazsonyi AT, Killias M (2001) Immigration and crime among youths in Switzerland. Criminal Justice and Behavior 28: 329-66.
x
Department of Psychiatry, University of Florida, Gainesville, United States
x
Department of Psychiatry, University of Florida, Gainesville, United States
*Corresponding author:
Korah T, Department of Psychiatry, University of Florida, Gainesville, FL 32610, United States, Tel: 352-265-5481, Email: korah@ufl.edu
Quick links
  • Peer Review
  • Publication Ethics
  • Plagiarism
  • Open Access
  • Waivers Policy

The Effectiveness of an E-Learning Program on Nurse’s Knowledge and Behavior for Caring of Patients with Thromboembolism: A Comparative Study

Raulerson T and Korah T*
Citation: Raulerson T, Korah T (2018) The Effectiveness of an E-Learning Program on Nurse’s Knowledge and Behavior for Caring of Patients with Thromboembolism: A Comparative Study. J Psychol Stu 1: 106
Received: 30 September 2018, Accepted: 10 December 2018, Published: 12 December 2018
Copyright: © 2018 Korah T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Psychosis is not necessarily a sign of a primary psychiatric disorder. New-onset psychosis requires extensive medical workup, including a thorough history and physical. A common etiology in patients with no prior psychiatric history is ingestion of a substance or medication that precipitates the symptoms. In this report, we present the case of a 66-year-old female with history of temporal lobe epilepsy who presented with auditory, visual, and tactile hallucinations, as well as paranoia regarding harm to herself and a family member. Onset of the symptoms occurred shortly after initiating topiramate. She had previously experienced suicidal ideation and personality changes on levetiracetam. Her neurologist initiated a cross-taper from topiramate to carbamazepine that was continued in the hospital. As this proceeded, her symptoms improved until she was free of hallucinations and was discharged. The diagnosis of psychotic disorder due to medication (topiramate) was made due to sudden onset of symptoms after initiating the treatment and was confirmed by prompt resolution of symptoms after discontinuation. This case demonstrates the importance of recognizing topiramate-induced psychosis, a rarely documented clinical phenomenon in older adults, across neurology, psychiatry, and other disciplines that prescribe this medication.

Keywords: Geriatric Psychiatry; Psychosis; Topiramate; Epilepsy

Introduction

Psychosis is an abnormal condition in which a person loses touch with reality and exhibits bizarre behavior in different grades of severity. However, psychosis is not necessarily a sign of a primary psychiatric disorder. Primary psychotic disorders, such as schizophrenia and the other disorders on its spectrum are therefore a diagnosis of exclusion [1]. Patients with new-onset psychosis require extensive medical workup to exclude other possible explanations for symptom onset [2]. A thorough history and physical examination is indispensable for finding a possible nonpsychiatric cause of the psychotic symptoms that may respond to interventions other than psychotropic medication. A common etiology for new-onset psychosis in patients with no prior psychiatric history is ingestion of a substance that precipitates the symptoms [1,3,4]. These substances range from recreational illicit drugs to various types of prescribed medications, including steroids, stimulants, and antiepileptics [5,6]. Topiramate, a positive allostatic modulator of GABAA receptors that causes an overall GABA mediated inhibition and higher GABA levels in brain, is one of such medication with unintended psychiatric manifestations [7]. Originally developed as an anti-diabetic drug, topiramate was later widely prescribed as an anti-convulsant medication due to its similarity to acetazolamide [8]. However, multiple reports have also identified induction of acute psychotic symptoms induced by topiramate in various treatment settings [9,10]. Although the use of topiramate for treatment of behavioral disturbances in geriatric patients are not uncommon, cases of psychotic symptoms associated with topiramate in older adults, is very rare [9-11]. Here we report a case of a female geriatric patient with depression and epilepsy who developed psychosis subsequent to topiramate treatment. This case adds to the literature as further evidence that this commonly prescribed medication should be considered in the differential diagnosis of late-onset and other atypically presenting psychotic illnesses, and evidence against the necessity of neuroleptics to treat the episode and achieve remission in older adults who may be more vulnerable to their adverse effects.

Case Presentation

Mrs. H. is a 66-year-old Caucasian female with a past medical history of temporal lobe epilepsy and unspecified depression who was presented to a psychiatric hospital, referred by her psychotherapist, for worsening auditory hallucinations of people talking to her, visual and tactile hallucinations of lasers going through her head, fears of hammers coming down from above to hurt her, and paranoia regarding her daughter. She had no history of primary psychiatric disorder and no prior episodes similar to her initial presentation. Mrs. H. started experiencing the symptoms subsequent to initiating topiramate treatment for her seizure disorder, about four months prior to admission. Her seizure disorder, initially diagnosed approximately 2 years prior to the psychotic episodes, was complex partial, confirmed by EEG, localized to the temporal lobe, consisted of stereotypical movements such as lip smacking with loss of consciousness, staring spells and post ictal tiredness and confusion. Although her seizure disorder was under control with levetiracetam, it also appeared to have induced depressed mood, personality changes, and suicidal ideation at its therapeutic dose for her epilepsy. Initial intervention by her neurologist was to cross taper Keppra while slowly titrating topiramate to an effective dose.Topiramate dose was increased while Keppra was decreased over a three-month treatment and the taper of levetiracetam was completed approximately three months prior to admission. The patient initially reported memory problems and trouble with speaking after switching to topiramate, however, these symptoms resolved itself. Though the exact timing of psychotic symptom onset was unclear, Mrs. H. was certain that she began seeing “ant people” and “praying for intergalactic peace” at a dose of 150 mg of topiramate twice daily. She mentioned these symptoms to her neurologist, who adjusted some other medications and continued the topiramate. She continued to experience hallucinations and then became paranoid, feeling unsafe in her own home due to dangerous objects approaching to harm her. Since she never had similar symptoms with levetiracetam, her neurologist began to decrease the topiramate, to 50 mg four times daily, and started carbamazepine, 400 mg nightly at bedtime. Her carbamazepine level at the time of admission was not detectable (less than 2.0 mcg/mL).

Throughout Mrs H.’s hospitalization, this lasted fifteen days, the team planned to continue cross-tapering her antiepileptics with goal to discontinue topiramate.Her lab reports on liver and kidney functions were within the normal ranges and she was not started on any neuroleptics. Topiramate (50 mg)four times/daily was immediately decreased to three times daily. She did start low-dose sertraline on day 2 for mood and anxiety symptoms in light of her previous suicidality, which was titrated to 50 mg daily on day 14. Carbamazepine was gradually increased to 700 mg per day by day 8, split 400 mg daily and 300 mg nightly. Her initial level at this dosage was 7.2 mcg/ml, however, she continued to experience visual hallucinations of knives that were causing cuts on her arms and gashes on her legs. At that time, taper of topiramate continued, with reduction to 50 mg twice daily, and then to 50 mg once daily on day 10. After complete discontinuation on day 13, her symptoms became “less terrifying” and gradually subsided. She was discharged from the hospital on the above 700 mg daily dose of carbamazepine with follow-up one week later at an outside facility, having maintained a carbamazepine level of 6.4 mcg/ml measured on day 14. Due to the sudden onset of the symptoms shortly after initiation of treatment with topiramate, she was given a diagnosis of substance-induced psychosis secondary to topiramate. This diagnosis was further supported by the resolution of symptoms once the medication was discontinued. Carbamazepine was ruled out as a causative factor in this case, since the symptoms were presentwhen the agent was undetectable and resolved on an increased dose in therapeutic range.

Discussion

Psychotic symptoms are often associated with other medical conditions, including epilepsy, or precipitated by ingestion of substances, including several antiepileptic medications [1,4,6]. Both categories of external causes must be ruled out prior to making a primary psychiatric diagnosis. This case, and at least three others in the literature, represents evidence that topiramate is a precipitant of acute psychotic symptoms at dosages exceeding 50mg daily [12-15]. Patients described in these reports, including for indications as seemingly benign as migraine prophylaxis, experienced paranoid delusions, hallucinations, depersonalization, suicidal ideation, severe mood swings, and impaired cognition [13]. Despite the known effects on precipitating psychotic symptoms, topiramate is being widely prescribed as a regimen for obesity control and weight loss, in addition to its canonical use in the treatment of epilepsy [16-18]. Similarly, in addition to its much-noticed psychogenic effects, reports on other undesirable side effects of topiramate also is on the rise [19,20]. Although implicated as one of the ‘potentially inappropriate medication (PIM)’ for geriatric patients with Alzheimer dementia, topiramate has been increasingly prescribed as one of the new generation antiepileptic drugs in treating older adults with epileptic disorders [21-22]. Here we report a case of a 66-year-old female presented to an inpatient geriatric psychiatry unit with severe psychotic symptoms subsequent to topiramate intake. The patient in this study experienced onset of symptoms at a total daily topiramate dose of 300 mg, which was initially continued and later decreased modestly to a total dose of 200 mg, still four times the minimum dose implicated by the previous reports. While the psychosis, like primary schizophrenia spectrum disorders, responds to neuroleptics, it can resolve completely with reduction of dose or discontinuation of topiramate, obviating the need for additional medication exposure. Although depression-related psychosis and potential roles of polypharmacy cannot be ruled out in this case, the observation that Mrs. H.’s symptoms did not completely subside until total discontinuation of the offending medication strongly suggest a stronger association of topiramate to her psychotic episode. Further, normal liver and kidney functions in this patient, as suggested by the laboratory reports also eliminated the possibility of adverse drug metabolism as apotential precipitating factor. However, the possibility that topiramate acts as a poor monotherapy antiepileptic agent in elderly, resulting in breakthrough partial seizure activity leading to ictal, inter ictal, and postictal psychosis, cannot be ruled out. Whenever the underlying mechanism and precipitating factors for the development of psychotic symptoms is unclear in a patient treated with topiramate, or other antiepileptic medications including carbamazepine, the treating physician should evaluate carefully for this potential adverse effect [12]. Since topiramate is being prescribed for increasing numbers of indications across various specialties, incidence and prevalence of topiramate-induced psychosis requires further clinical attention to avoid exacerbations that result in otherwise avoidable psychiatric hospital admissions and possible unnecessary exposure to neuroleptics [23]. Especially important is to apply these considerations for geriatric patients who may have multiple cooccurring physical and mental health issues.

Disclosures

Consent for publication: Institutional consent form obtained from the patient is available upon request.

Authors’ contributions

TR acquired clinical information and contributed interpretations of general medical events described in the manuscript.

TK conceived the study, provided major background and discussion points, interpretations of psychiatric events described in the manuscript, and prepared the manuscript.

Both TR and TK read, revised and approved the final manuscript.

Acknowledgment

The authors would like to thank Camilo Leal, MD, and Jennifer Davis, DO, for presenting this report as a poster presentation at the APA 2016 Atlanta, GA, meeting.

References

x1. Lieberman JA, First MB (2018) Psychotic Disorders. N Engl J Med 379: 270-80.
x2. McKee J, Brahm N (2016) Medical mimics: Differential diagnostic considerations for psychiatric symptoms. Ment Health Clin 6: 289-96.
x3. Addington J, Cornblatt BA, Cadenhead KS, Cannon TD, McGlashan TH, et al. (2011) At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry 168: 800-5.
x4. Buchy L, Cadenhead KS, Cannon TD, Cornblatt BA, McGlashan TH, et al. (2015) Substance use in individuals at clinical high risk of psychosis. Psychol Med 45: 2275-84.
x5. Smith B, Dubovsky SL (2017) Pharmacotherapy of mood disorders and psychosis in pre- and post-natal women. Expert Opin Pharmacother 16: 1703-19.
x6. Chen B, Choi H, Hirsch LJ, Katz A, Legge A, et al. (2017) Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav 76: 24-31.
x7.White HS (2003) Mechanism of action of newer anticonvulsants. J Clin Psychiatry 64: 5-8.
x8. Manhapra A, Chakraborty A, Arias AJ (2018) Topiramate Pharmacotherapy for Alcohol Use Disorder and Other Addictions: A Narrative Review. J Addict Med.
x9. Singh T (2006) Topiramate and psychosis. Psychiatry 12: 10-7.
x10. Gupta PP, Thacker AK, Haider J, Dhawan S, Pandey N, et al. (2014) Assessment of topiramate’s efficacy and safety in epilepsy. J Neurosci Rural Pract 2: 144-8.
x11. Mowla A, Pani A (2010) Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial. J Clin Psychopharmacol 30: 40-3.
x12. Khan A, Faught E, Gilliam F, Kuzniecky R (1999) Acute psychotic symptoms induced by topiramate. Seizure 8: 235-7.
x13. Miller AD, Prost VM, Bookstaver PB, Gaines KJ (2010) Topiramate-induced myoclonus and psychosis during migraine prophylaxis. AmJHealth Syst Pharm 67:1178-80.
x14. Watkin A, Alam F, Qaiser J (2010) Topiramate-induced psychosis: the picture at 12 months. BMJ Case Rep : 0720103141.
x15. Kanner AM, Wuu J, Faught E, Tatum WO, Fix A, et al. (2003) A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav 4: 548-52.
x16. Grandone A, Di Sessa A, Umano GR, Toraldo R, Miraglia Del Giudice E (2018) New treatment modalities for obesity.Best Pract Res Clin Endocrinol Metab 32: 535-49.
x17. Iwaki H, Jin K, Fujikawa M, Nakasato N, Kaneko S (2018) Topiramate-induced weight loss depends on level of intellectual disability in patients with epilepsy.Epilepsy Behav 83: 87-91.
x18. Patel DK, Stanford FC (2018) Safety and tolerability of new-generation anti-obesity medications: a narrative review. Postgrad Med 130: 173-82.
x19. Khera R, Pandey A, Chandar AK, Murad MH, Prokop LJ, et al. (2018) Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis.Gastroenterol 154: 1309-19.
x20. Lai YH, Ding YJ, Moses D, Chen YH (2017) Teratogenic Effects of Topiramate in a Zebrafish Model. Int J Mol Sci E1721.
x21. Kaufman KR, Newman NB, Dawood A (2014) Capgras delusion with violent behavior in Alzheimer dementia: case analysis with literature review.Ann Clin Psychiatry 26: 187-91.
x22. Theitler J, Brik A, Shaniv D, Berkovitch M, Gandelman-Marton R (2017) Antiepileptic Drug Treatment in Community-Dwelling Older Patients with Epilepsy: A Retrospective Observational Study of Old- Versus New-Generation Antiepileptic Drugs. Drugs Aging 34: 479-87.
x23. Bonnett L, Smith CT, Smith D, Williamson P, Chadwick D, et al. (2012) Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial. Lancet Neurol 11: 331-40.
x
9. Singh T (2006) Topiramate and psychosis. Psychiatry 12: 10-7.
10. Gupta PP, Thacker AK, Haider J, Dhawan S, Pandey N, et al. (2014) Assessment of topiramate’s efficacy and safety in epilepsy. J Neurosci Rural Pract 2: 144-8.
11. Mowla A, Pani A (2010) Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial. J Clin Psychopharmacol 30: 40-3.
x
12. Khan A, Faught E, Gilliam F, Kuzniecky R (1999) Acute psychotic symptoms induced by topiramate. Seizure 8: 235-7.
13. Miller AD, Prost VM, Bookstaver PB, Gaines KJ (2010) Topiramate-induced myoclonus and psychosis during migraine prophylaxis. AmJHealth Syst Pharm 67:1178-80.
14. Watkin A, Alam F, Qaiser J (2010) Topiramate-induced psychosis: the picture at 12 months. BMJ Case Rep : 0720103141.
15. Kanner AM, Wuu J, Faught E, Tatum WO, Fix A, et al. (2003) A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav 4: 548-52.
x
16. Grandone A, Di Sessa A, Umano GR, Toraldo R, Miraglia Del Giudice E (2018) New treatment modalities for obesity.Best Pract Res Clin Endocrinol Metab 32: 535-49.
17. Iwaki H, Jin K, Fujikawa M, Nakasato N, Kaneko S (2018) Topiramate-induced weight loss depends on level of intellectual disability in patients with epilepsy.Epilepsy Behav 83: 87-91.
18. Patel DK, Stanford FC (2018) Safety and tolerability of new-generation anti-obesity medications: a narrative review. Postgrad Med 130: 173-82.
x
21. Kaufman KR, Newman NB, Dawood A (2014) Capgras delusion with violent behavior in Alzheimer dementia: case analysis with literature review.Ann Clin Psychiatry 26: 187-91.
22. Theitler J, Brik A, Shaniv D, Berkovitch M, Gandelman-Marton R (2017) Antiepileptic Drug Treatment in Community-Dwelling Older Patients with Epilepsy: A Retrospective Observational Study of Old- Versus New-Generation Antiepileptic Drugs. Drugs Aging 34: 479-87.
x
54. Penha AM, Burkhardt E, Schaeffel F, Feldkaemper MP (2012) Effects of intravitreal insulin and insulin signaling cascade inhibitors on emmetropization in the chick. Mol Vis18: 2608-22.
55. Lin SF, Lin PK, Chang FL, Tsai RK (2009) Transient hyperopia after intensive treatment of hyperglycemia in newly diagnosed diabetes. Ophthalmologica 223: 68-71.
56. Feldkaemper MP, Neacsu I, Schaeffel F (2009) Insulin acts as a powerful stimulator of axial myopia in chicks. Invest Ophthalmol Vis Sci 50: 13-23.
57. Zhu ZC, Zhang JS, Ji XY, Wang YF, Chen Y, et al. (2007) Insulin-like growth factor-1 induced activation and expression of signal transducers and activators of transcription-3 in scleral fibroblast of guinea pigs [Article in Chinese]. Zhonghua Yan Ke Za Zhi 43: 1125-9.
x
81. Grenet T, Streho M, Nicolon L, Puech M, Chaine G (2011) A case report of transient myopia following blunt trauma [Article in French]. J Fr Ophtalmol 34: 127.e1-4.
82. Küchle M, Naumann GO (2003) Transient myopia after trauma. Ophthalmology 110: 1285-6.
83. Ikeda N, Ikeda T, Nagata M, Mimura O (2002) Pathogenesis of transient high myopia after blunt eye trauma. Ophthalmology 109: 501-7.
84. Doğanay S, Er H, Hepşen IF, Evereklioğlu C (2001) Bilateral myopia following blunt trauma to one eye. Eur J Ophthalmol 11: 83-5.
85. Guerriero S, Ciracì L, Cardia G, Vetrugno M (2010) Transient myopic shift as the presenting symptom of systemic lupus erythematosus: a UBM study. Ocul Immunol Inflamm 18: 383-4.
x
86. Hung KC, Hsueh PY, Wang NK, Su WW, Tan HY (2011) Transient myopic shifting in systemic lupus erythematosus. Lupus 20: 334-5.
87. Bohgaki T, Mukai M, Notoya A, Kondo M, Kohno M, et al. (2001) Transient myopia with severe chemosis as an initial manifestation of systemic lupus erythematosus. Mod Rheumatol 11: 165-7.
88. Shu U, Takeuchi F, Tanimoto K, Moroi Y, Uchida K, et al. (1992) Transient myopia with severe chemosis associated with exacerbation of disease activity in systemic lupus erythematosus. J Rheumatol 19: 297-301.
x
x13. Hall W, Degenhardt L (2007) Prevalence and correlates of cannabis use in developed and developing countries. Curr Opin Psychiatry 20: 393-7.
x14. Weir E (2000) Raves: a review of the culture, the drugs and the prevention of harm. CMAJ 162: 1843-8.
x15. Van Havere T, Vanderplasschen W, Broekaert E, De Bourdeaudhui I (2009) The Influence of Age and Gender on Party Drug Use Among Young Adults Attending Dance Events, Clubs, and Rock Festivals in Belgium. Substance Use & Misuse 44: 1899-915.
x16. Van Havere T, Vanderplasschen W, Lammertyn J, Broekaert E, Bellis M (2011) Drug use and nightlife: more than just dance music. Subst Abuse Treat Prev Policy 6: 18.
x17. Donath C, Gräßel E, Baier D, Pfeiffer C, Karagülle D, et al. (2011) Alcohol consumption and binge-drinking in adolescents: comparison of different migration backgrounds and rural vs. urban residence-a representative study. Donath et al. BioMed Central (BMC) Public Health 11: 84
x18. Fergusson DM, Lynskey MT, Horwood LJ (1996) Alcohol misuse and juvenile offending in adolescence. Addiction 91: 483-94.
x
x23. Duke A A, Smith K M Z, Oberleitner L M S, Westphal A, McKee S A (2018) Alcohol, drugs, and violence: A meta-meta-analysis. Psychology of Violence 8: 238-49.
x24. Marihuana: A Signal of Misunderstanding (1972) National Commission on Marihuana and Drug Abuse. Chapter III. Social Impact of Marihuana Use. Report. Commissioned by President Richard M. Nixon, March, 1972. Iova University.
x25. Killias M, Kuhn A, Aebi MF (2011) Ground plan of criminology. A European perspective (Grundriss der Kriminologie. Eine Europeische Perspektive) 2nd edn. Bern: Stämpfli Verlag AG Bern.
x
x27. Pliner P, Cappell H, Miles CG (1972) Observer judgments of intoxicated behavior during social interaction: a comparison of alcohol and marijuana, in Drug Addiction, edited by Singh JM, Miller LH, Lal H Mt. Kisco, NY: Futura Publishing, 1972, pp 59-67. Quoted by Moss HB, Tarter RE (1993) Substance Abuse, I Aggression, and Violence. What Are the Connections? The American J Addict 2:149-60.
x28. Reiss A J, Roth J A (1993) Alcohol, other psychoactive drugs and violence. In A J Reiss, J A Roth (Eds.), Understanding and preventing violence.Washington, DC: National Academy Press: 182–220.
x29. Boles SM, Miotto K (2003) Substance abuse and violence: A review of the literature. Aggression and violent behavior 8: 155-74.
x
x30. Otero-Lopez JM, Luengo-Martin A, Miron-Redondo L, Carrillo-De-La-Peña M T, Romero-Trinanes E (1994) An Empirical Study of the Relations Between Drug Abuse and Delinquency Among Adolescents. Br J Criminol 34: 459-78.
x31. Calafat A, Mantećon A, Juan M, Adrover-Roig D, Blay N, et al. (2011) Violent Behaviour, Drunkness, Drug use, and Social Capital in Nightlife Context. Psychosocial Intervention 20: 45-51.
x32. Hoaken PN, Stewart SH (2003) Drugs of abuse and the elicitation of human aggressive behavior. Addictive behavior 28: 1533-54.
x33. Roth J A (1994) Psychoactive Substances and Violence. Research in Brief, US Dept. of Justice.
x34. Manzoni P, Lucia S, Schwarzenegger C (2011) Feasibility study on the dark field survey in the area of “youth and violence”. Final Report. On behalf of the Federal Social Insurance Office (BSV). Criminological Institute University of Zurich (Machbarkeitsstudie zur Dunkelfeldbefragung im Bereich “Jugend und Gewalt”. Schlussbericht. Im Auftrag des Bundesamts für Sozialversicherungen (BSV). Kriminologisches Institut Universität Zürich) 149.
x35. Moore T M, Gregory L S (2005) Review of the literature on marijuana and interpersonal violence. Aggression and Violent Behavior 10: 171-92.
x
x14. Weir E (2000) Raves: a review of the culture, the drugs and the prevention of harm. CMAJ 162: 1843-8.
x15. Van Havere T, Vanderplasschen W, Broekaert E, De Bourdeaudhui I (2009) The Influence of Age and Gender on Party Drug Use Among Young Adults Attending Dance Events, Clubs, and Rock Festivals in Belgium. Substance Use & Misuse 44: 1899-915.
x16. Van Havere T, Vanderplasschen W, Lammertyn J, Broekaert E, Bellis M (2011) Drug use and nightlife: more than just dance music. Subst Abuse Treat Prev Policy 6: 18.
x
x46. RCT – randomized controlled trial.
x47. Kivivuori J, Salmi V, Walser S (2013) Supervision mode effects in computerized delinquency surveys at school: Finnish replication of a Swiss experiment. Journal of Experimental Criminology 9: 91-107.
x48. Walser S, Killias M (2012) Who should supervise students during self-report interviews? A controlled experiment on response behavior in online questionnaires. J Exp Criminol 8: 17-28.
x
x14. Weir E (2000) Raves: a review of the culture, the drugs and the prevention of harm. CMAJ 162: 1843-8.
x15. Van Havere T, Vanderplasschen W, Broekaert E, De Bourdeaudhui I (2009) The Influence of Age and Gender on Party Drug Use Among Young Adults Attending Dance Events, Clubs, and Rock Festivals in Belgium. Substance Use & Misuse 44: 1899-915.
x16. Van Havere T, Vanderplasschen W, Lammertyn J, Broekaert E, Bellis M (2011) Drug use and nightlife: more than just dance music. Subst Abuse Treat Prev Policy 6: 18.
x17. Donath C, Gräßel E, Baier D, Pfeiffer C, Karagülle D, et al. (2011) Alcohol consumption and binge-drinking in adolescents: comparison of different migration backgrounds and rural vs. urban residence-a representative study. Donath et al. BioMed Central (BMC) Public Health 11: 84
x18. Fergusson DM, Lynskey MT, Horwood LJ (1996) Alcohol misuse and juvenile offending in adolescence. Addiction 91: 483-94.
x
x6. Police Crime Statistics (PKS) (2013) Annual Report 2012. Section Crime and Criminal Law. Federal Statistical Office (FSO) (Polizeiliche Kriminalstatistik (PKS) (2013). Jahresbericht 2012. Sektion Kriminalität und Strafrecht. Herausgeber - Bundesamt für Statistik (BFS)). Neuchâtel.
x7. Police Crime Statistics (PKS) (2014) Annual Report 2013. Crime and Criminal Justice Section. Federal Statistical Office (FSO) (Polizeiliche Kriminalstatistik (PKS) (2014). Jahresbericht 2013. Sektion Kriminalität und Strafrecht. Herausgeber - Bundesamt für Statistik (BFS)). Neuchâtel.
x8. Police Crime Statistics (PKS) (2015) Annual Report 2014 Crime and Criminal Law Section. Federal Statistical Office (FSO) (Polizeiliche Kriminalstatistik (PKS) (2015) Jahresbericht 2014. Sektion Kriminalität und Strafrecht. Herausgeber - Bundesamt für Statistik (BFS)). Neuchâtel.
x9. Killias M (1997) Immigrants, crime, and criminal justice in Switzerland. In M. Tonry (Ed.), Ethnicity, crime, and immigration: Comparative and cross-national perspectives. Chicago: University of Chicago Press: 375-406.
x10. Vazsonyi AT, Killias M (2001) Immigration and crime among youths in Switzerland. Criminal Justice and Behavior 28: 329-66.
























1. Article title
2. Abstract
3. Introduction
4. Case Presentation
5. Discussion
6. Disclosures
7. Authors’ contributions
8. Acknowledgment
9. References

Table and Figures

  • TABLES
  • FIGURES
table-icon
Table 1
table-icon
Table 2
image-icon
Figure 1
image-icon
Figure 2

SUBMIT MANUSCRIPT

Easy and hassle free submission process.

Partnered Content Networks

  • Cancer Science
  • Vaccine Studies
  • Gynecology
  • Food Nutrition
  • Nursing Science
  • Public Health
  • The Pharma
  • Infectious Disease
  • Neuro Care
  • Catalysis
  • Neonatal Biology
  • Neonatal Disorders
  • Mutation
  • Nanotechnology
  • Toxicology
  • Dark Biotechnology
  • Pollution Toxicology
  • Cell Biology
  • Bioanalytical Research
  • Renal Disorders
  • The Astrophysics
  • Sleep Physiology
  • Epidemiology
  • Histology
SCHOLARENA

Scholarena, an open access publication dedicated to the scientific community.

  • contact@scholarena.com
  • P: +1-6602142040
  • 415 Grover Street

    Warrensburg, MO - 64093, USA

USEFUL LINKS
  • About
  • Join Editorial Board
  • For Authors
  • For Editors
  • Open Access Statement
  • Peer Review Policy
  • Publication Ethics
  • Waivers Policy
  • Plagiarism Policy
VIEW ARTICLES
High Infant Mortality and Morbidity in Fluoridated Soft Water U.S. States Use of Zygomatic Implants for Atrophic Maxilla Rehabilitation - A Clinical Case Report of Unilateral Zygomatic Implant Structural and Optical Characteristics of Cu Doped Sno2 Nanostructures Adverse Effects of Covid-19 Vaccines Among Medical Students: A Cross-Sectional Study High Signal Intensity in the Dentate Nucleus on Unenhanced T1-Weighted MR Images in Melanoma Patients Receiving Macrocyclic Gadolinium-Based Contrast Human Osteoblast Growth and Maturation in Response to Metformin and the Thienopyridone, A769662 A Rapidly Progressive Hydatid Disease Imitating Metastatic Malignancy: An Unusual Multi-Organ Presentation. Report of a Case and Review of Literature Radiographic Evaluation of the Appearance and Closure Time of Growth Plates of Radius and Ulna Bones in Nigerian Indigenous Dogs Pathogenic variants in KPTN gene identified by Clinical Whole-Genome Sequencing
Subscribe

Sign up for our mailing list to get latest updates and offers.

We respect your privacy

  • HOME
  • ABOUT
  • SUBMIT MANUSCRIPT
  • CONTACT

Creative Commons License Open Access by Scholarena is licensed under a Creative Commons Attribution 4.0 License.